Seborrheic dermatitis

Journal of the European Academy of Dermatology and Venereology

Volumn 18, Issue 1, 2004, Pages 13-26

  Gupta, A K ^a,b,c   Bluhm, R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

Dermatitis; Fungus; Malassezia; Review; Seborrheic

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BENZOYL PEROXIDE; BETAMETHASONE BENZOATE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; BIFONAZOLE; CICLOPIROX; CINNAMIC ACID; COAL TAR; CORTICOSTEROID; FLUCONAZOLE; GRISEOFULVIN; HYDROCORTISONE; ITRACONAZOLE; KERATOLYTIC AGENT; KETOCONAZOLE; METRONIDAZOLE; MICONAZOLE; PROPYLENE GLYCOL; PYRITHIONE ZINC; SELENIUM SULFIDE; SUCCINATE LITHIUM; TERBINAFINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIINFLAMMATORY ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIAPER DERMATITIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LIVER TOXICITY; MALASSEZIA; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIORAL DERMATITIS; PRIORITY JOURNAL; PUVA; REVIEW; RISK FACTOR; SEBORRHEIC DERMATITIS; SKIN ATROPHY; TELANGIECTASIA; TREATMENT PLANNING;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DERMATITIS, SEBORRHEIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALASSEZIA;

EID: 0742289615     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00693.x     Document Type: Review

References (196)

1. Burton JJ, Pye RJ. Seborrhoea is not a feature of seborrheic dermatitis. Br Med J (Clin Res Ed) 1983; 286: 1169-1170.
2. Christiansen JV. The paradox of seborrheic dermatitis: a man, a mind and a myth. Acta Derm Venereol (Suppl.) (Stockh) 1985; 120: 90-92.
3. Piérard-Franchimont C, Hermanns J, Degreef H et al. From axioms to new insights into dandruff. Dermatology 2000; 200: 93-98.
4. Priestly GC, Savin JA. The microbiology of dandruff. Br J Dermatol 1976; 94: 469-470.
5. Kligman AM, McGinley KJ, Leyden JJ. The nature of dandruff. J Soc Cosmetic Chem 1976; 27: 111-139.
6. Bulmer AC, Bulmer GS. The antifungal action of dandruff shampoos. Mycopathologica 1999; 147: 63-65.
7. McGrath J, Murphy GM. The control of seborrheic dermatitis and dandruff by antipityrosporal drugs. Drugs 1991; 41: 178-184.
8. Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatology 1989; 6: 80-84.
9. Yegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol (Stockh) 1983; 63: 335-339.
10. Kligman AM. Perspectives and problems in cutaneous gerontology. J Invest Dermatol 1979; 73: 39-46.
11. Lynch PJ. Dermatologic problems of the head and neck in the aged. Otolaryngol Clin North Am 1982; 15: 271-285.
12. Halder RM. Hair and scalp disorders in blacks. Cutis 1983; 32: 378-380.
13. Kenney JA Jr. Dermatoses seen in American Negroes. Int J Dermatol 1970; 70: 110-113.
14. Halder RM, Grimes PE, McLaurin CI et al. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis 1983; 32: 388-390.
15. Ostlere LS, Taylor CR, Harris DW et al. Skin surface lipids in HIV-positive patients with and without seborrheic dermatitis. Int J Dermatol 1996; 35: 276-279.
16. Hale EK, Bystryn JC. Relation between skin temperature and location of facial lesions in seborrheic dermatitis [letter]. Arch Dermatol 2000; 136: 559-600.
17. Bergbrant I-M, Johansson S, Robbins D et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol 1991; 16: 331-338.
18. Lifson AR, Hessol NO, Buchbinder SP et al. The association of clinical conditions and serologic tests with CD4+ lymphocyte counts in HIV-infected subjects without AIDS. AIDS 1991; 5: 1209-1215.
19. Oranje AP, van Joost T, van Reede EC et al. Infantile seborrheic dermatitis. Morphological and immunological study. Dermatologica 1986; 171: 191-195.
20. Brenner S, Horwitz C. Possible nutrient mediators in psoriasis and seborrheic dermatitis. II. Nutrient mediators; essential fatty acids; vitamins A, E and D; vitamins B1, B2, B6, niacin and biotin; vitamin C; selenium; zinc; iron. World Rev Nutr Diet 1988; 55: 165-182.
21. Brenner S, Horwitz C. Possible nutrient mediators in psoriasis and seborrheic dermatitis. I. Prevalence, etiology, symptomatology, histological and biochemical features. World Rev Nutr Diet 1988; 22: 153-164.
22. Pekarek RS, Sandstead HH, Jacob RA et al. Abnormal cellular immune responses during acquired zinc deficiency. Am J Clin Nutr 1979; 32: 1466-1471.
23. Balnave D. Clinical symptoms of biotin deficiency in animals. Am J Clin Nutr 1977; 30: 1408-1413.
24. Wahlberg JE, Liden C. Is the skin affected by work at visual display terminals? Dermatol Clin 1988; 6: 81-85.
25. Lidén C, Wahlberg JE. Work with video display terminals among office employees. V. Dermatologic factors. Scand J Work Environ Health 1985; 11: 489-493.
26. Rosset M, Oki G. Skin diseases in alcoholics. O J Stud Alcohol 1971; 32: 1017-1024.
27. Shellow WV. The skin in alcoholism. Int J Dermatol 1983; 22: 506-510.
28. Maietta G, Rongioletti F, Rebora A. Seborrheic dermatitis and daylight [letter]. Acta Derm Venereol 1993; 73: 396.
29. Barba A, Piubello W, Vantini I et al. Skin lesions in chronic alcoholic pancreatitis. Dermatologica 1982; 164: 322-326.
30. Maietta G, Fornaro P, Rongioletti F et al. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol 1990; 70: 432-434.
31. Barbeau A. Dopamine and disease. Can Med Assoc J 1970; 103: 824-832.
32. Binder RL, Jonelis FJ. Seborrheic dermatitis in neuroleptic-induced Parkinsonism. Arch Dermatol 1983; 119: 473-475.
33. Marino CT, McDonald E, Romano JF. Seborrheic dermatitis in acquired immunodeficiency syndrome. Cutis 1991; 50: 217-218.
34. Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1985; 13: 947-951.
35. Cribier B, Samain F, Vetter D et al. Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol 1992; 72: 454-455.
36. Clift DC, Dodd JH, Kirby JD et al. Seborrheic dermatitis and malignancy. An investigation of the skin flora. Acta Derm Venereol 1988; 68: 48-52.
37. Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Genet 1996; 50: 317-320.
38. Marren P, Burge S. Seborrhoeic dermatitis of the scalp - a manifestation of Hailey-Hailey disease in a predisposed individual? Br J Dermatol 1992; 126: 294-296.
39. Gross-Tsur V, Gross-Kieselstein E, Amir N. Cardio-facio cutaneous syndrome: neurological manifestations. Clin Genet 1990; 38: 382-386.
40. Saboraud R. Maladies Desquamataities. Paris, 1904.
41. MacKee GM, Lewis GM. Dandruff and seborrhea I. Flora of normal and diseased scalps. J Invest Dermatol 1938; 1: 31.
42. Bergbrant I-M, Faergemann J. Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm Venereol (Stockh) 1989; 69: 332-335.
43. McGinley KJ, Leyden JJ, Marples RR et al. Quantitative microbiology of the scalp in non-dandruff, dandruff and seborrhoeic dermatitis. J Invest Dermatol 1975; 64: 401-405.
44. Heng MCY, Henderson CL, Barker DC et al. Correlation of Pityrosporum ovale density with clinical severity of sebhorrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23: 82-86.
45. Leyden JJ, McGinley JK, Kligman AM. Role of microorganisms in dandruff. Arch Dermatol 1976; 112: 333-338.
46. Ford GP, Farr PM, Ive FA et al. The response of seborrheic dermatitis to ketoconazole. Br J Derm 1984; 111: 603-609.
47. Ortonne J-P, Lacour J-P, Vitetta A et al. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrheic dermatitis in adults. Dermatology 1992; 184: 275-280.
48. Guého E, Midgley G, Guillot J. The genus Malassezia with description of four new species. Antonie Van Leeuwenhoek 1996; 69: 337-355.
49. Gupta AK, Kohli Y, Summerbell RC et al. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001; 39: 243-251.
50. Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 2000; 38: 337-341.
51. Sandström MH, Bartosik J, Bäck O et al. The prevalence of the Malassezia yeasts in patients with atopic dermatitis, seborrheic dermatitis and healthy controls [abstract]. JEADV 2001; 15 (Suppl. 2): 104-274.
52. Cowley NC, Farr PM. A dose-response study of irritant reactions to sodium lauryl sulphate in patients with seborrhoeic dermatitis and atopic eczema. Acta Derm Venereol (Stockh) 1992; 72: 432-435.
53. Sudan BJL. Seborrheic dermatitis induced by nicotine of horsetails (Equisetum arvense L.). Contact Dermatitis 1985; 13: 201-202.
54. Sudan BL, Brouillard C, Sterboul J et al. Nicotine as a hapten in seborrheic dermatitis. Contact Dermatitis 1984; 11: 196-197.
55. Midgley G, Hay RJ. Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and Western blotting. Bull Soc Fr Med Mycol 1988; 17: 267-276.
56. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139: 254-263.
57. Faergemann J, Bergbrant I-M, Dohsé M. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144: 549-556.
58. Gupta AK. A random survey concerning aspects of acne rosacea [abstract]. J Cut Med Surg 2001; 5 (Suppl.): 38.
59. Zug KA, Palay DA, Rock B. Dermatologic diagnosis and treatment of itchy red eyelids. Surv Ophthalmol 1996; 40: 293-306.
60. McCulley JP, Dougherty JM. Blepharitis associated with acne rosacea and seborrheic dermatitis. Int Ophthalmol Clin 1985; 25: 159-172.
61. McCulley JP, Dougherty JM, Deneeau DG. Classification of chronic blepharitis. Ophthalmology 1982; 89: 1173-1180.
62. Reisner RM. Acne vulgaris. Pediatr Clin N Am 1973; 20: 851-864.
63. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis 1998; 61: 65-72.
64. Faergemann J, Johansson S, Bäck O. An immunologic and cultural study of Pityrosporum folliculitis. J Am Acad Dermatol 1986; 14: 429-433.
65. Ackerman AB. Histopathologic differentiation of eczematous dermatitis from psoriasis and seborrheic dermatitis. Cutis 1977; 20: 619-623.
66. Civatte A. Psoriasis and seborrheic eczema: pathological anatomy and diagnostic histology of the two dermatoses. Br J Derm Syph 1924; 36: 461.
67. Pinkus H, Mehregan AH. The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Derm 1966; 46: 109-116.
68. Leyden JJ. Diaper dermatitis. Dermatol Clin 1986; 4: 23-28.
69. Leung AK. Neonatal seborrheic dermatitis [letter]. West J Med 1985; 142: 558.
70. Yates VM, Kerr RE, MacKie RM. Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis - clinical features. Br J Dermatol 1983; 108: 633-638.
71. Vickers CFH. The natural history of atopic eczema. Acta Dermato-Venereol Suppl 1980; 92: 113.
72. Podmore P, Burrows D, Eedy DJ et al. Seborrhoeic eczema - a disease entity or a clinical variant of atopic eczema? Br J Dermatol 1986; 115: 341-350.
73. Clemmenson OJ, Hjorth N. Treatment of atopic dermatitis of the head and neck with ketoconazole in patients with type I sensitivity to Pityrosporum orbiculare. Semin Dermatol 1983; 2: 26-29.
74. Broberg A, Faergemann J. Infantile seborrheic dermatitis and Pityrosporum ovale. Br J Dermatol 1989; 120: 359-362.
75. Tollesson A, Frithz A, Stenlund K. Malassezia furfur in infantile seborrheic dermatitis. Pediatr Dermatol 1997; 14: 423-425.
76. Ruiz-Maldonado R, Lopez-Matinez R, Perez Chavarria EL, Rocio Castanon L, Tamayo L. Pityrosporum ovale in infantile seborrheic dermatitis. Pediatr Dermatol 1989; 6: 16-20.
77. Andersen SL, Thomsen K. Psoriasiform napkin dermatitis. Br J Dermatol 1971; 84: 316-319.
78. Neville EA, Finn OA. Psoriasiform napkin dermatitis - a follow-up study. Br J Dermatol 1975; 92: 279-285.
79. Ilchyshyn A, Meldelsohn SS, Macfarlane A et al. Candida albicans and infantile seborrhoeic dermatitis. Br J Clin Pract 1987; 41: 557-559.
80. Leyden JJ, Migman AM. The role of microorganisms in diaper dermatitis. Arch Dermatol 1978; 114: 56-59.
81. Leiner C. Uber Erythrodermia desquamativa, eine eingenartige universelle Dermatose der Brustkinder. Arch Dermatol Syphilol 1908; 89: 163-189.
82. Odom RB, James WB, Berger TG. Andrew's Diseases of the Skin, 9th edn. Philadelphia, PA: W.B. Saunders, 2000.
83. Friedlander SF, West A, Eichenfield LF. Isolated leukemia cutis presenting as 'seborrheic dermatitis'. Clin Pediatr 1996; 35: 531-534.
84. Henderson CA, Taylor J, Cunliffe WJ. Sebum excretion rates in mothers and neonates. Br J Dermatol 2000; 142: 110-111.
85. Tollesson A, Frithz A, Berg A et al. Essential fatty acids in infantile seborrheic dermatitis. J Am Acad Dermatol 1993; 28: 957-961.
86. Nisenson A, Barness LA. Treatment of seborrheic dermatitis with biotin and vitamin B complex. J Pediatr 1972; 8: 630-631.
87. Kalayci O, Coskun T, Tokatli A et al. Infantile spasms as the initial symptom of biotinidase deficiency. J Pediatr 1994; 124: 103-103.
88. Erlichman M, Goldstein R, Levi E et al. Infantile flexural seborrhoeic dermatitis. Neither biotin nor essential fatty acid deficiency. Arch Dis Child 1981; 56: 560-562.
89. Podmore P, Burrows D, Eedy D. T-cell subset assay. A useful differentiating marker of atopic and seborrheic eczema in infancy? Arch Dermatol 1988; 124: 1235-1238.
90. Yates VM, Kerr RE, Frier K et al. Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis - total and specific IgE levels. Br J Dermatol 1983; 108: 639-645.
91. Nisenson A. Seborrheic dermatitis of infants: treatment with biotin injections for the nursing mother. Pediatrics 1969; 18: 211-217.
92. Keipert JA. Oral use of biotin in seborrhoeic dermatitis of infancy: a controlled trial. Med J Aust 1976; 1: 584-585.
93. Tollesson A, Frithz A. Borage oil, an effective new treatment for infantile seborrhoeic dermatitis [letter]. Br J Dermatol 1993; 129: 95.
94. Torpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988; 118: 517-522.
95. Rogers SC, Burrows D, Neill D. Percutaneous absorption of phenol and methyl alcohol in Magenta Paint B.P.C. Br J Dermatol 1978; 98: 559-560.
96. Shohat M, Mimouni M, Varsano I. Efficacy of topical application of glucocorticosteroids compared with eosin in infants with seborrheic dermatitis. Cutis 1987; 40: 67-68.
97. Shobat M, Mimouni M, Shuper A et al. Adrenocortical suppression by topical application of glucocorticosteroids in infants with seborrheic dermatitis. Clin Pediatr 1986; 25: 209-212.
98. Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1: 542-544.
99. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986; 115: 475-484.
100. Taieb A, Legrain V, Palmier C et al. Topical ketoconazole for infantile seborrhoeic dermatitis. Dermatologica 1990; 181: 26-32.
101. Berger S, Stoner MF, Hobbs ER et al. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol 1988; 19: 298-303.
102. Barton JC, Buchness MR. Nongenital dermatologic disease in HIV-infected women. J Am Acad Dermatol 1999; 40: 938-948.
103. Prose N. HIV infection in children. J Am Acad Dermatol 1990; 22: 1223-1231.
104. Mahe A, Boulais C, Blanc L et al. Seborrheic dermatitis as a revealing feature of HIV infection in Bamako, Mali [letter]. Int J Dermatol 1994; 33: 601-602.
105. Mahe A, Simon F, Coulibaly S. Predictive value of seborrheic dermatitis and other common dermatoses for HIV infection in Bamako, Mali. J Am Acad Dermatol 1998; 38: 1084-1086.
106. Eisenstat BA, Wormser GP. Seborrheic dermatitis and butterfly rash in AIDS [letter]. N Engl J Med 1984; 311: 189.
107. Soeprono FF, Schinella RA, Cockerell CJ et al. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. J Am Acad Dermatol 1986; 14 (2 Part 1): 242-248.
108. Alessi E, Cusini M, Zerboni R. Mucocutaneous manifestations in patients infected with human immunodeficiency virus. J Am Acad Dermatol 1988; 19 (2 Part 1): 290-297.
109. Matis WL, Triana A, Shapiro R et al. Dermatologic findings associated with human immunodeficiency virus infection. J Am Acad Dermatol 1987; 17: 46-51.
110. Senaldi G, Di Perri G, Di Silverio, A et al. Seborrhoeic dermatitis: an early manifestation in AIDS [letter]. Clin Exp Dermatol 1987; 12: 72-73.
111. Vidal C, Girard PM, Dompmartin D et al. Seborrheic dermatitis and HIV infection. Qualitative analysis of skin surface lipids in men seropositive and seronegative for HIV. J Am Acad Dermatol 1990; 23 (6 Part 1): 1106-1110.
112. Puig L, Fernandez-Figueras T, Ferrandiz C et al. Epidermal expression of 65 and 72 kD heat shock proteins in psoriasis and AIDS-associated psoriasiform dermatitis. J Am Acad Dermatol 1995; 33: 985-989.
113. Skinner RB, Zanolli MD, Noah PW et al. Seborrheic dermatitis and acquired immunodeficiency syndrome [letter]. J Am Acad Dermatol 1986; 14: 147-148.
114. Wikler JR, Nieboer C, Willemze R. Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. J Am Acad Dermatol 1992; 27: 37-39.
115. Buchness MR. Treatment of skin diseases in HIV-infected patients. Dermatol Clin 1995; 13: 231-238.
116. Coldiron BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 1989; 125: 357-361.
117. Goodman DS, Teplitz ED, Wishner A et al. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. J Am Acad Dermatol 1987; 17: 210-220.
118. Dann FJ, Tabibian P. Cutaneous diseases in human immunodeficiency virus-infected patients referred to the UCLA Immunosuppression Skin Clinic: reasons for referral and management of select diseases. Cutis 1995; 55: 85-88.
119. Cohn T. Encephalitis ohne Lethargie wahrend der Grippe epidemie. Zentralblatt Neurochiurgie 1920; 39: 260.
120. Krfstin D. The seborrhoeic facies as a manifestation of postencephalitic Parkinsonism and allied disorders. Q J Med 1927; 21: 177.
121. Burton JL, Cartlidge M, Cartlidge NEF, Shuster S. Sebum excretion in Parkinsonism. Br J Dermatol 1973; 88: 263-266.
122. Cowley NC, Farr RM, Shuster S. The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol 1990; 122: 71-76.
123. Burton JL, Shuster S. Effect of L-Dopa on seborrhoea of Parkinsonism. Lancet 1970; 2(7662): 19-20.
124. Martignoni E, Godi L, Pacchetti C et al. Is seborrhea a sign of autonomic impairment in Parkinson's disease? J Neural Transm 1997; 104: 1295-1304.
125. Shuster S, Thody AJ, Goolamali SK et al. Melanocyte-stimulating hormone and Parkinsonism. Lancet 1973; 1(7801): 463-464.
126. Burton JL, Cartlidge M, Shuster S. Effect of L-Dopa on the seborrhoea of Parkinsonism. Br J Dermatol 1973; 88: 475-479.
127. Sandyk R, Pardeshi R. Topographic subtypes of tardive dyskinesia: relationship to seborrhea [letter]. Intern J Neuroscience 1990; 54: 321-323.
128. Sandyk R. Seborrhea and persistent tardive dyskinesia. Intern J Neurosci 1990; 50: 223-236.
129. Sandyk R, Kay SR. The relationship of negative schizophrenia to Parkinsonism. Intern J Neurosci 1990; 55: 1-59.
130. Christodoulou GN, Vareltzides AG. Positive side effects of lithium? [letter]. Am J Psychiatry 1978; 135: 10.
131. Christodoulou GN, Georgala S, Vareltzides A et al. Lithium in seborrheic dermatitis. Psychiatr J University Ott 1983; 8: 27-29.
132. Yung CY. A review of clinical trials of lithium in medicine. Pharmacol Biochem Behav 1984; 21 (Suppl. 1): 51-54.
133. Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132: 441-445.
134. Lin AN, Reimer RJ, Carter DM. Sulfur revisited. J Am Acad Dermatol 1998; 18: 553-558.
135. Orentreich N, Taylor EH, Berger RA et al. Comparative study of two antidandruff preparations. J Pharm Sci 1969; 58: 1279-1280.
136. Fredriksson T. Controlled comparison of Clinitar shampoo and Selsun shampoo in the treatment of seborrheic dermatitis. Br J Clin Pract 1985; 39: 25-28.
137. Olansky S. Whole coal tar shampoo: a therapeutic hair repair system. Cutis 1980; 25: 99-104.
138. Garcia RL, Miller JD, Miller JN. Occlusive tar extract therapy for recalcitrant psoriasis and seborrheic dermatitis of the scalp. Cutis 1978; 22: 90-91.
139. Gould DJ, Mortimer PS, Proby C et al. A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 1992; 26: 452-457.
140. Culelenaere C, De Bersaques J, Kint A. Use of topical lithium succinate in the treatment of seborrhoeic dermatitis. Dermatology 1992; 184: 194-197.
141. Langtry JAA, Rowland Payne CME, Staughton RDC et al. Topical lithium succinate ointment (Efalith) in the treatment of AIDS-related seborrheic dermatitis. Clin Exp Dermatol 1997; 22: 216-219.
142. Leeming JP, Burton JL. Lithium succinate and seborrhoeic dermatitis: an antifungal mode of action? [letter]. Br J Derm 1990; 122: 718-719.
143. Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrheic dermatitis. Br Med J 1986; 292: 28.
144. Bonnetblanc JM, Bernard P. Benzoyl peroxide in seborrheic dermatitis. Arch Dermatol 1986; 122: 752.
145. Faergemann J. Short-term treatment of dandruff with a combination of propylene glycol solution and shampoo. Cutis 1988; 42: 146.
146. Christiansen JV, Gadborg E, Kleiter I et al. Efficacy of Bufexamac (NFN) cream in skin diseases: a double-blind, multicentre trial. Dermatologica 1977; 154: 177-184.
147. Dahl KB, Reymann F. Photochemotherapy in erythrodermic seborrheic dermatitis [letter]. Arch Dermatol 1977; 113: 1295-1296.
148. Lloyd KM. The value of neomycin in topical corticosteroid preparations. South Med J 1969; 62: 94-96.
149. Cullen SI. Selective evaluation of a new topical steroid (betamethasone benzoate). Curr Ther Res Clin Exp 1968; 10: 270-275.
150. Harris JJ. A national double-blind clinical trial of a new corticosteroid lotion: a 12-investigator cooperative analysis. Curr Ther Res Clin Exp 1972; 14: 638-646.
151. Marks R, Bhogal B, Wilson L. The effect of betamethasone valerate on seborrheic dermatitis of the scalp: a clinical, histopathological and cell kinetic study. Acta Derm Venereol (Stockh) 1974; 54: 373-375.
152. Rosenberg EW. Fluocinonide: preliminary evaluation of a new topically applied corticosteroid. Arch Derm 1971; 104: 632-633.
153. Binder R, McCleary J. Comparison of fluocinonide in a double-blind study with betamethasone valerate. Curr Ther Res Clin Exp 1972; 14: 35-38.
154. Len F. Complications from prolonged topical steroid therapy [letter]. J Am Acad Dermatol 1983; 8: 425-426.
155. Nierman MM. Safety and efficacy of clocortolone pivalate 0.1 percent cream in the treatment of atopic dermatitis, contact dermatitis and seborrheic dermatitis. Cutis 1981; 27: 670-671.
156. Morman MR. Possible side effects of topical steroids. Am Fam Physician 1981; 23: 171-174.
157. Weber G. Rosacea-like dermatitis: contraindication or intolerance reaction to strong steroids. Br J Dermatol 1972; 86: 253-259.
158. Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician 2000; 61: 2703-2710.
159. Guin JD. Complications of topical hydrocortisone. J Am Acad Dermatol 1981; 4: 417-422.
160. Brauer EW, Opdyke DL, Burnett CM. The anti-seborrheic qualities of zinc pyrithione (zinc-pyridine-2-thiol-2-oxide) in a cream vehicle. J Invest Dermatol 1966; 47: 174-176.
161. Marks R, Pearse AD, Walker AP. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112: 415-522.
162. Opdyke DL, Burnett CM, Brauer EW. Anti-seborrhoeic qualities of zinc pyrithione in a cream vehicle. II. Safety evaluation. Fd Cosmet Toxicol 1967; 5: 321-326.
163. Veien NK, Pilgaard CE, Gade M. Seborrhoeic dermatitis of the scalp treated with a tar/zinc pyrithione shampoo. Clin Exp Dermatol 1979; 4: 53-56.
164. Segal R, David M, Ingber A. Treatment with bifonazole shampoo for seborrhea and seborrheic dermatitis: a randomized, double-blind study. Acta Derm Venereol (Stockh) 1992; 72: 454-455.
165. Shiri J, Amachai B. Treatment of seborrheic dermatitis of the scalp and dandruff with a shampoo containing 1% bifonazole (Agispor shampoo). J Dermatol Treat 1998; 9: 95-96.
166. Zienicke H, Korting HC, Braun-Falco O et al. Comparative efficacy and safety of bifonazole 1% cream and the corresponding base preparation in the treatment of seborrheic dermatitis. Mycoses 1993; 36: 325-331.
167. Shemer A, Nathanson N, Kaplan B et al. Treatment of scalp seborrheic dermatitis and psoriasis with and ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000; 39: 521-538.
168. Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol 1986; 114: 695-700.
169. Farr PM, Shuster S. Treatment of seborrheic dermatitis with topical ketoconazole [letter]. Lancet 1984, 2(8414): 1271-1272.
170. Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole. II. Response of seborrheic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol 1987; 116: 217-221.
171. Peter RU, Korting HC. Behandlung des seborrhoischen Ekzems mit Ketoconazol im Vergleich zu einer Wirkstoff-freien Pflegecreme. Arzneimittelforschung 1991; 41: 852-854.
172. Skinner RB, Noah PW, Taylor RM. Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J Am Acad Dermatol 1985; 12: 852-856.
173. Carr MM, Pryce DM, Ive FA. Treatment of seborrhoeic dermatitis with ketoconazole. I. Response of seborrhoeic dermatitis of the scalp to topical ketoconazole. Br J Dermatol 1987; 116: 213-216.
174. Piéard-Franchimont C, Piérard GE, Arrese JE et al. Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrheic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001; 202: 171-176.
175. Dobrev H, Zissova L. Effect of ketoconazole 2% shampoo on scalp sebum level in patients with seborrheic dermatitis. Acta Derm Venereol (Stockh) 1997; 77: 132-134.
176. Piérard GE, Piérard-Franchimont C, Van Cutsem J et al. Ketoconazole 2% emulsion in the treatment of seborrheic dermatitis. Int J Dermatol 1991; 30: 806-809.
177. Danby FW, Maddin WS, Margesson LJ et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008-1012.
178. Stratigos JD, Antoniou C, Katsambas A et al. Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis: a double-blind comparative study. J Am Acad Dermatol 1988; 19: 850-853.
179. Rigopoulos D, Katsambas A, Antoniou C. Facial seborrheic dermatitis treated with fluconazole 2% shampoo. Int J Dermatol 1994; 33: 136-137.
180. Parsad D, Pandhi R, Negi KS et al. Topical metronidazole in seborrheic dermatitis - a double-blind study. Dermatology 2001; 202: 35-37.
181. Iudica AC. Does treatment with topical metronidazole improve seborrheic dermatitis? J Fam Pract 2001; 50: 492.
182. Anonymous. Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7: 574-583.
183. Hanel H, Smith Kurtz E, Pastowsky S. Therapy of seborrhoeic eczema with an antifungal agent with an antiphlogistic effect. Mycoses 1991; 34 (Suppl. 1): 91-93.
184. Vardy DA, Zvulunov A, Tchetov T et al. A double-blind, placebo-controlled trial of ciclopiroxolamine 1% shampoo for treatment of scalp seborrheic dermatitis. J Dermatol Treatment 2000; 11: 73-77.
185. Dupuy P, Maurette C, Amoric JC. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144: 1033-1037.
186. Aly R, Katz I, Kempers SE, Lookingbill D et al. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatol 2003; 42 (Suppl. 1): 19-22.
187. Petranyi G, Ryder NS, Stütz A. Allylamine derivatives: a new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239-1241.
188. Faergemann J, Jones TC, Hettler O et al. Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrhoeic dermatitis: new treatment options. Br J Dermatol 1996; 134 (Suppl. 46): 12-15.
189. Baroni A, De Rosa R, De Rosa A et al. New strategies in dandruff treatment: growth control of Malassezia ovalis. Dermatology 2000; 201: 332-336.
190. Al-Waili NS. Therapeutic and prophylactic effects of crude honey on chronic seborrheic dermatitis and dandruff. Eur J Med Res 2001; 30: 306-308.
191. Caputo R, Barbareschi M, Gorani A et al. Itraconazole: new horizons [abstract]. JEADV 2001; 15 (Suppl. 2): 93.
192. Caputo R, Barbareschi M. Itraconazole: new horizons. Giornale Italiano di dermatological e venereologica 2002; 137: 1-7.
193. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14: 124-127.
194. Scapparo E, Quadri G, Virno G et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil®) in patients with seborrheic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001; 144: 854-857.
195. Cauwenbergh G, Degreef H, Heykants J et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-268.
196. Faergemann J, Zehnender H, Denouel J et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis, sebum, hair and nails during and after 250 mg terbinafine orally once per day for 4 weeks. Acta Derm Venereol (Stockh) 1993; 73: 305-309.